- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06379282
Undersöker rollen av modifiering av energibalansen på hälsosvar vid kronisk lymfatisk leukemi (HIT-CLL)
This randomised control clinical trial aims to investigate the effects of exercise training and diet on physical and functional fitness and immunological and metabolic changes in adults with chronic lymphocytic leukaemia. Investigators will randomise participants to either 12 weeks of supervised/semi-supervised exercise only, exercise + nutritional guidance, or no exercise.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
This study aims to perform a randomised control trial of exercise or exercise plus nutritional guidance on the physiological and immunological health of adults diagnosed with chronic lymphocytic leukaemia (CLL). Recruited participants will be randomised to either 12 weeks of an exercise-only program, an exercise-plus nutritional guidance program or a no-exercise control group. Fasting blood samples collected at Baseline and 12 weeks will measure absolute CLL cell counts, immune function, and inflammatory and metabolic biomarkers. A series of physical fitness assessments will be assessed at baseline and 12 weeks to determine physiologic reserve and resilience against external stressors. Additionally, participants will be asked to return 12 weeks after completing the intervention to assess the legacy effects of the intervention on the same physiological and blood-based biomarkers of health.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Guildford, Storbritannien, GU2 7WG
- University of Surrey
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Confirmed diagnosis of CLL (including small lymphocytic leukaemia) as per the International Workshop on CLL Guidelines.
- Male or female ≥ 18 years of age
- Able to walk on a treadmill or cycle on an ergometer
- Pass the Physical Activity Readiness Questionnaires (PAR-Q and PAR-Q+)
Exclusion Criteria:
- Corticosteroid therapy initiated less than 7 days before study entry. Prednisone 10mg or less or equivalent is allowed. Topical or inhaled corticosteroids are permitted.
- Secondary malignancy within 3 years of study enrollment requiring intervention except for adequately treated basal, squamous cell carcinoma or non-melanomatous skin cancer, carcinoma in situ of the cervix, superficial bladder cancer not treated with intravesical chemotherapy or BCG within 6 months, localised prostate cancer and PSA stable.
- Absolute contraindications to exercise: Recent (<6 months) acute cardiac event unstable angina, uncontrolled dysrhythmias causing symptoms or hemodynamic compromise, symptomatic aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolus, acute myocarditis or pericarditis, suspected or known dissecting aneurism and acute systemic infection.
- Significant orthopaedic limitations, musculoskeletal disease and/or injury. Due to the nature of the study, persons with known joint, muscle or other orthopaedic limitations that restrict physical activity may be excluded.
- Type I diabetes mellitus or uncontrolled Type II diabetes mellitus, or chronic obstructive pulmonary disease
- Uncontrolled blood pressure (≥180/90) at rest
- Known concurrent HIV, Hepatitis B or Hepatitis C
- Unable to comply with other study requirements
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: HIT Group
Exercise Only
|
Exercise training only |
|
Experimentell: EXE+ Group
Exercise + Nutritional Guidance
|
Exercise Training + Nutritional Guidance |
|
Inget ingripande: Control Group
Control group will receive no exercise or nutritional guidance |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from baseline in absolute number of CD19+/CD5+ CLL cells at week 12
Tidsram: Baseline and 12 weeks
|
A blood sample will be taken and assessed for CD19+/CD5+ CLL frequency using flow cytometry and total lymphocyte counts to determine the absolute number of CLL cells in x10^9/L |
Baseline and 12 weeks
|
|
Change from baseline in cardiorespiratory fitness (CRF: VO2peak) at week 12
Tidsram: Baseline and 12 weeks
|
Cardiopulmonary exercise testing will be conducted to assess changes in fitness |
Baseline and 12 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Frailty
Tidsram: Baseline and 12 weeks
|
Frailty will be determined by a series of validated physical function tests that provide a score of 0-1(Robust), 2 (Pre-Frail), 3-5 (Frail) |
Baseline and 12 weeks
|
|
Muscle Strength and Endurance
Tidsram: Baseline and 12 weeks
|
Estimated one repetition maximum and repetitions to failure using machine-based weights |
Baseline and 12 weeks
|
|
Muscle Health
Tidsram: Baseline and 12 weeks
|
Ultrasound and near-infrared spectroscopy assessment of muscle fuel usage |
Baseline and 12 weeks
|
|
Change in Quality of Life using the EORCT-QLQ-C30
Tidsram: Baseline and 12 weeks
|
Quality of life will be determined by the EORCT-QLQ-C30 questionnaire |
Baseline and 12 weeks
|
|
Change in muscle oxygen metabolism during a single bout of exercise
Tidsram: Baseline and 12 weeks
|
Measurement of muscle oxygenation via near infrared spectroscopy during a single session of acute exercise |
Baseline and 12 weeks
|
|
Change in B-CLL Cell Function
Tidsram: Baseline and 12 weeks
|
Measurement of in vitro B-CLL cell proliferation by flow cytometry |
Baseline and 12 weeks
|
|
Change in systemic and cellular bioenergetics
Tidsram: Baseline and 12 weeks
|
Measurement of in vitro immune cell fuel utilisation by high resolution respirometry and mass spectrometry |
Baseline and 12 weeks
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Legacy Effect of Intervention on change in cardiorespiratory fitness (VO2peak) as measured by a cardiopulmonary exercise test
Tidsram: 12 weeks to 24 weeks
|
Reassessment of CRF following 12 weeks of unguided exercise training |
12 weeks to 24 weeks
|
|
Legacy Effect of Intervention on absolute number of CD19+/CD5+ CLL cells
Tidsram: 12 weeks to 24 weeks
|
Reassessment of absolute number of CD19+/CD5+ CLL cells following 12 weeks of unguided exercise training |
12 weeks to 24 weeks
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: David Bartlett, PhD, University of Surrey
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Kronisk sjukdom
- Sjukdomsegenskaper
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Hematologiska sjukdomar
- Lymfatiska sjukdomar
- Lymfoproliferativa störningar
- Immunproliferativa störningar
- Leukemi, B-cell
- Leukemi, lymfoid
- Leukemi
- Patologiska tillstånd, tecken och symtom
- Hemiska och lymfsjukdomar
- Svaghet
- Neoplasmer
- Leukemi, lymfocytisk, kronisk, B-cell
Andra studie-ID-nummer
- FHMS 21-22 263 EGA
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .